安罗替尼联合PD-1抑制剂后线治疗晚期上皮性卵巢癌的疗效及安全性分析

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Advanced Epithelial Ovarian Cancer

目的探讨安罗替尼联合PD-1抑制剂后线治疗晚期上皮性卵巢癌患者的疗效和安全性。方法回顾性分析33例经标准二线或三线治疗失败的晚期上皮性卵巢癌患者资料,所有患者均接受安罗替尼联合PD-1抑制剂治疗,收集治疗期间疗效及安全性数据。结果客观缓解率为36.4%(95%CI:20.4%~54.9%),疾病控制率为81.8%(95%CI:64.5%~93.0%)。中位无进展生存期和总生存期分别为7.6月(95%CI:3.1~12.1月)和19.6月(95%CI:15.1~24.1月)。常见的治疗相关不良反应为疲劳(66.7%)、恶心和呕吐(54.5%)、高血压(48.5%)和腹泻(39.4%)。Cox回归分析显示:ECOG PS评分和FIGO分期是影响安罗替尼联合PD-1抑制剂治疗晚期上皮性卵巢癌无进展生存期的独立影响因素。结论安罗替尼联合PD-1抑制剂后线治疗晚期上皮性卵巢癌初步表现出较好的疗效,不良反应可耐受。

Objective To investigate the efficacy and safety of anlotinib combined with PD-1 blockades for patients with advanced epithelial ovarian cancer(EOC).Methods A retrospective study was performed,enrolling 33 patients with advanced EOC who failed standard systematic therapy.All patients were administered with anlotinib combined with PD-1 blockades.The efficacy and safety profile were determined during treatment.Results The objective response rate of the 33 patients was 36.4%(95%CI:20.4%-54.9%)and the disease control rate of the patients was 81.8%(95%CI:64.5%-90.0%).The median PFS and OS of the 33-patient cohort were 7.6 months(95%CI:3.1-12.1)and 19.6 months(95%CI:15.1-24.1),respectively.The most common treatment-related adverse reactions were fatigue(66.7%),nausea and vomiting(54.5%),hypertension(48.5%),and diarrhea(39.4%).Furthermore,multivariate Cox regression analysis indicated that ECOG performance status and FIGO stage were independent factors for predicting the PFS of the combination regimen for patients with advanced EOC.Conclusion Anlotinib combined with PD-1 blockades preliminarily exhibit satisfactory efficacy and tolerable safety profile for patients with advanced EOC.